IAG’s Leadership Expands with Appointment of Chief Financial Officer and Chief Technology Officer

IAG’s Leadership Expands with Appointment of Chief Financial Officer and Chief Technology Officer

IAG’s Leadership Expands with Appointment of Chief Financial Officer and Chief Technology Officer

London, UK and Philadelphia, USA—IAG, Image Analysis Group, a strategic partner to life science companies committed to its ambitious goal of bringing the best of technological innovation, AI and quantitative imaging to optimize the speed, cost and time of bio-pharmaceutical R&D, today announced the appointment of Richard Nichol as Chief Financial Officer and Prof. Jamshid Dehmeshki as Chief Technology Officer.

Richard Nichol, joining IAG in March 2020 as a CFO, is a qualified accountant and an experienced hands-on Chief Financial Officer with 20+ years of experience in the pharmaceutical R&D, software and high-tech industries, supporting growth in private and PE backed companies. Most recently Richard has overseen growth in turnover from £3.2m to £22m and staff from 50 to over 300 across UK, Europe and USA with responsibility for implementation and development of all financial, tax, corporate governance and office facility functions within a group with offices in UK, US and EU. He will be bringing board level management, financial, governance and M&A experience to support IAG’s ambition for global expansion and M&A.

” I have been extremely impressed with the management team at IAG, the vision they have for the Company and their execution to date.  I am looking forward to joining at such an exciting time for IAG and being part of the team that will use its technical innovation in imaging to help life-science companies find solutions to improve patient outcomes”.

Jamshid Dehmeshki, who joined IAG in January 2020 to take over from Mark Hinton, is a computer science professor who has combined his 20+ years of academic career with commercial appointments in top pharma and medtech companies. His background is in AI, medical image analysis, data mining, algorithm developments, mathematical, stochastic and forecasting modelling and numerical analysis. He has published more than 170 scientific research papers, five book chapters and holds thirteen patents. He has delivered  several Computer Aided Diagnosis (CAD) products  to identify, quantify and characterise diseases with FDA and CE certificate.

Jamshid will be taking DYNAMIKA, our cloud-based proprietary software platform for imaging clinical trial management to the next level. We will share the updates of our plans and the progress of this exciting development in due course.

‘We envisage that 2020 will be a step-change year for IAG. We are planning for geographical expansion and further development of our technology platform DYNAMIKA that will incorporate our novel algorithms and methodologies designed to accelerate drug development when it comes to measuring efficacy in rheumatology, musculoskeletal, immunology and oncology clinical research studies,’ said Dr. Olga Kubassova, CEO of IAG.

‘I am delighted to welcome Richard and Jamshid, who are joining our fantastic management team, whose commitment and enthusiasm already saw IAG through 100% growth in 2019,’ said Christophe Berthoux, Chair of IAG.

 

About IAG, Image Analysis Group

IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core expertise in medical imaging, AI, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com

News
Events